ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Sells $750,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey sold 50,000 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the transaction, the chief operating officer now directly owns 6,024 shares in the company, valued at $90,360. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY traded up $0.24 during midday trading on Monday, reaching $13.20. The stock had a trading volume of 876,687 shares, compared to its average volume of 715,928. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -24.92 and a beta of 0.87. The company’s 50 day moving average price is $10.43 and its 200 day moving average price is $9.36. ARS Pharmaceuticals, Inc. has a twelve month low of $2.55 and a twelve month high of $16.50.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $2.00 million. Equities analysts forecast that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. lifted its holdings in ARS Pharmaceuticals by 14.8% during the 1st quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock valued at $110,999,000 after buying an additional 1,401,299 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of ARS Pharmaceuticals by 37.0% during the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock worth $29,500,000 after purchasing an additional 779,969 shares during the period. ClariVest Asset Management LLC purchased a new position in ARS Pharmaceuticals during the first quarter valued at $2,790,000. Jacobs Levy Equity Management Inc. boosted its position in shares of ARS Pharmaceuticals by 1,280.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 277,706 shares of the company’s stock valued at $2,838,000 after acquiring an additional 257,589 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of ARS Pharmaceuticals by 5.9% during the 4th quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock worth $22,460,000 after purchasing an additional 229,988 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SPRY. Cantor Fitzgerald assumed coverage on shares of ARS Pharmaceuticals in a research report on Tuesday, August 20th. They set an “overweight” rating and a $30.00 price objective for the company. Raymond James upgraded ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Finally, Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $22.75.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.